Likewise, Ampio has yet to explain why the clear failure of a small study of its experimental drug Optina in diabetic macular edema was spun as a success.
A phase III study of Optina in diabetic macular edema is now underway, even though its design falls well short of what's necessary for FDA approval.
Ampio is happy to accuse short sellers of attacking the company but can't respond intelligently to criticisms about a subpar phase III Optina study.
As Dredly also points out correctly, Ampio has also missed or changed its guidance about the development of the osteoarthritis drug Ampion, without explanation. Why did the company change the primary endpoint of a phase II study conducted in Australia last year? Why did the company first claim to reach agreement with the FDA to begin phase III studies of Ampion but then concede the need for a phase II study?On these important questions, Ampio remains silent. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts